Fresenius Med Cr Financials
Financial Health Signals
Based on FY2016 annual data. Scores normalized against common benchmarks. How we calculate these scores
Fresenius Med Cr has an operating margin of 14.7%, meaning the company retains $15 of operating profit per $100 of revenue. This strong profitability earns a score of 74/100, reflecting efficient cost management and pricing power. This is up from 13.9% the prior year.
Fresenius Med Cr's revenue grew 7.0% year-over-year to $17.9B, a solid pace of expansion. This earns a growth score of 49/100.
Fresenius Med Cr carries a low D/E ratio of 0.67, meaning only $0.67 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.
Fresenius Med Cr's current ratio of 1.45 indicates adequate short-term liquidity, earning a score of 38/100. The company can meet its near-term obligations, though with limited headroom.
Fresenius Med Cr has a free cash flow margin of 6.2%, earning a moderate score of 31/100. The company generates positive cash flow after capital investments, but with room for improvement.
Fresenius Med Cr's ROE of 11.5% shows moderate profitability relative to equity, earning a score of 46/100. This is up from 10.4% the prior year.
Fresenius Med Cr scores 2.15, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Fresenius Med Cr passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Fresenius Med Cr generates $1.72 in operating cash flow ($2.1B OCF vs $1.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Fresenius Med Cr earns $5.8 in operating income for every $1 of interest expense ($2.6B vs $452.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
This page shows Fresenius Med Cr (FMS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Fresenius Med Cr generated $17.9B in revenue in fiscal year 2016. This represents an increase of 7.0% from the prior year.
Fresenius Med Cr's EBITDA was $3.4B in fiscal year 2016, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.1% from the prior year.
Fresenius Med Cr generated $1.1B in free cash flow in fiscal year 2016, representing cash available after capex. This represents an increase of 10.2% from the prior year.
Fresenius Med Cr reported $1.2B in net income in fiscal year 2016. This represents an increase of 20.8% from the prior year.
Fresenius Med Cr earned $4.06 per diluted share (EPS) in fiscal year 2016. This represents an increase of 20.1% from the prior year.
Fresenius Med Cr held $747.2M in cash against $7.2B in long-term debt as of fiscal year 2016.
Fresenius Med Cr paid $0.80 per share in dividends in fiscal year 2016. This represents an increase of 2.6% from the prior year.
Fresenius Med Cr had 306M shares outstanding in fiscal year 2016. This represents an increase of 0.3% from the prior year.
Fresenius Med Cr's gross margin was 32.3% in fiscal year 2016, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.
Fresenius Med Cr's operating margin was 14.7% in fiscal year 2016, reflecting core business profitability. This is up 0.8 percentage points from the prior year.
Fresenius Med Cr's net profit margin was 6.9% in fiscal year 2016, showing the share of revenue converted to profit. This is up 0.8 percentage points from the prior year.
Fresenius Med Cr's ROE was 11.5% in fiscal year 2016, measuring profit generated per dollar of shareholder equity. This is up 1.1 percentage points from the prior year.
Fresenius Med Cr invested $162.4M in research and development in fiscal year 2016. This represents an increase of 15.7% from the prior year.
Fresenius Med Cr invested $1.0B in capex in fiscal year 2016, funding long-term assets and infrastructure. This represents an increase of 8.1% from the prior year.
FMS Income Statement
| Metric | Q4'16 | Q3'16 | Q2'16 | Q1'16 | Q4'15 | Q3'15 | Q2'15 | Q1'15 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7B+1.9% | $4.6B+4.0% | $4.4B+5.1% | $4.2B-49.4% | $8.3B+96.2% | $4.2B+0.8% | $4.2B+110480.4% | $3.8M |
| Cost of Revenue | $3.1B-1.0% | $3.1B+3.5% | $3.0B+4.7% | $2.9B+0.3% | $2.9B+1.0% | $2.8B-1.8% | $2.9B+4.5% | $2.8B |
| Gross Profit | $1.6B+8.2% | $1.5B+5.2% | $1.4B+6.1% | $1.3B-75.7% | $5.4B+292.6% | $1.4B+6.5% | $1.3B+146.8% | -$2.8B |
| R&D Expenses | $42.2M-3.8% | $43.9M+13.2% | $38.8M+3.4% | $37.5M-6.2% | $39.9M+14.3% | $34.9M+1.3% | $34.5M+11.5% | $30.9M |
| SG&A Expenses | $767.2M-2.5% | $786.8M+7.5% | $732.1M-3.5% | $758.5M-2.2% | $775.7M+4.5% | $742.3M+2.7% | $722.6M+10.3% | $654.9M |
| Operating Income | $786.2M+17.4% | $669.9M+4.5% | $641.1M+18.7% | $540.3M-18.4% | $661.8M+7.9% | $613.5M+12.2% | $547.0M+8.4% | $504.4M |
| Interest Expense | $106.0M-3.5% | $109.9M-8.4% | $119.9M+3.0% | $116.4M-6.8% | $124.9M+17.9% | $105.9M-8.0% | $115.1M-29.0% | $162.0M |
| Income Tax | $212.2M+29.2% | $164.2M-2.5% | $168.4M+21.8% | $138.3M-23.4% | $180.5M+7.1% | $168.4M+24.4% | $135.4M-1.8% | $137.9M |
| Net Income | $388.1M+16.5% | $333.2M+13.3% | $293.9M+28.9% | $228.0M-28.0% | $316.8M+20.8% | $262.3M+9.0% | $240.8M+14.9% | $209.5M |
| EPS (Diluted) | N/A | N/A | N/A | $0.75 | N/A | $0.86 | N/A | $0.69 |
FMS Balance Sheet
| Metric | Q4'16 | Q3'16 | Q2'16 | Q1'16 | Q4'15 | Q3'15 | Q2'15 | Q1'15 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $26.9B+1.0% | $26.7B+0.4% | $26.6B+1.9% | $26.1B+2.8% | $25.4B-0.2% | $25.4B0.0% | $25.4B+1.2% | $25.1B |
| Current Assets | $7.3B+1.3% | $7.2B-0.8% | $7.3B+1.8% | $7.1B+5.6% | $6.8B+0.1% | $6.8B+0.9% | $6.7B+1.6% | $6.6B |
| Cash & Equivalents | $747.2M+18.6% | $629.8M-12.9% | $722.7M+39.6% | $517.8M-5.8% | $549.5M-11.6% | $621.4M+6.7% | $582.2M-6.5% | $622.9M |
| Inventory | $1.4B+0.2% | $1.4B+1.6% | $1.4B-0.1% | $1.4B+3.3% | $1.3B+1.6% | $1.3B+9.3% | $1.2B+4.2% | $1.2B |
| Accounts Receivable | $3.5B-2.7% | $3.6B+4.4% | $3.5B-3.7% | $3.6B+9.6% | $3.3B-0.1% | $3.3B+0.8% | $3.3B+3.0% | $3.2B |
| Goodwill | $13.7B+1.3% | $13.5B+0.5% | $13.4B+2.1% | $13.2B+0.9% | $13.0B0.0% | $13.0B-0.3% | $13.1B+0.4% | $13.0B |
| Total Liabilities | $14.2B+0.3% | $14.2B-2.1% | $14.5B+2.3% | $14.2B+2.4% | $13.8B-2.6% | $14.2B-1.1% | $14.4B+1.6% | $14.1B |
| Current Liabilities | $5.0B-4.1% | $5.3B+6.8% | $4.9B+10.6% | $4.4B+7.2% | $4.1B+5.5% | $3.9B+8.8% | $3.6B+1.9% | $3.5B |
| Long-Term Debt | $7.2B+0.4% | $7.2B-6.9% | $7.7B-1.8% | $7.8B-0.1% | $7.9B-6.0% | $8.4B-5.1% | $8.8B+2.3% | $8.6B |
| Total Equity | $10.8B+2.1% | $10.6B+4.0% | $10.2B-0.1% | $10.2B+3.1% | $9.9B+2.7% | $9.6B+0.6% | $9.6B+0.2% | $9.6B |
| Retained Earnings | $8.8B+4.6% | $8.4B+4.1% | $8.1B+0.2% | $8.1B+2.9% | $7.9B+4.2% | $7.6B+3.6% | $7.3B-0.3% | $7.3B |
FMS Cash Flow Statement
| Metric | Q4'16 | Q3'16 | Q2'16 | Q1'16 | Q4'15 | Q3'15 | Q2'15 | Q1'15 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $843.6M+92.2% | $438.9M-35.2% | $677.6M+276.9% | $179.8M-67.2% | $548.3M-5.3% | $579.3M | $0-100.0% | $832.5M |
| Capital Expenditures | $282.4M+16.9% | $241.5M-68.1% | $756.3M+402.3% | -$250.2M-181.9% | $305.6M+33.1% | $229.6M-72.5% | $835.5M+300.0% | -$417.8M |
| Free Cash Flow | $561.2M+184.4% | $197.3M+351.0% | -$78.6M-11.7% | -$70.4M-129.0% | $242.7M-30.6% | $349.7M+141.9% | -$835.5M-301.5% | $414.7M |
| Investing Cash Flow | -$451.4M-65.6% | -$272.6M+14.4% | -$318.2M+5.6% | -$337.1M-39.7% | -$241.3M+14.4% | -$281.8M | $0+100.0% | -$477.6M |
| Financing Cash Flow | -$266.9M-0.2% | -$266.5M-60.3% | -$166.3M-244.7% | $114.9M+130.8% | -$373.3M-55.2% | -$240.5M | $0+100.0% | -$393.8M |
| Dividends Paid | -$554.4M-200.0% | $554.4M+300.0% | -$277.2M | $0+100.0% | -$526.5M-200.0% | $526.5M+100.0% | $263.2M+200.0% | -$263.2M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
FMS Financial Ratios
| Metric | Q4'16 | Q3'16 | Q2'16 | Q1'16 | Q4'15 | Q3'15 | Q2'15 | Q1'15 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 34.0%+2.0pp | 32.0%+0.4pp | 31.6%+0.3pp | 31.3%-34.0pp | 65.3%+32.7pp | 32.7%+1.8pp | 30.9%+73038.0pp | -73007.1% |
| Operating Margin | 16.8%+2.2pp | 14.6%+0.1pp | 14.5%+1.6pp | 12.8%+4.9pp | 8.0%-6.5pp | 14.5%+1.5pp | 13.0%-13271.1pp | 13284.2% |
| Net Margin | 8.3%+1.0pp | 7.2%+0.6pp | 6.7%+1.2pp | 5.4%+1.6pp | 3.8%-2.4pp | 6.2%+0.5pp | 5.7%-5513.1pp | 5518.8% |
| Return on Equity | 3.6%+0.4pp | 3.1%+0.3pp | 2.9%+0.6pp | 2.2%-1.0pp | 3.2%+0.5pp | 2.7%+0.2pp | 2.5%+0.3pp | 2.2% |
| Return on Assets | 1.4%+0.2pp | 1.3%+0.1pp | 1.1%+0.2pp | 0.9%-0.4pp | 1.3%+0.2pp | 1.0%+0.1pp | 0.9%+0.1pp | 0.8% |
| Current Ratio | 1.45+0.1 | 1.37-0.1 | 1.48-0.1 | 1.61-0.0 | 1.63-0.1 | 1.72-0.1 | 1.850.0 | 1.86 |
| Debt-to-Equity | 0.67-0.0 | 0.68-0.1 | 0.76-0.0 | 0.77-0.0 | 0.79-0.1 | 0.87-0.1 | 0.92+0.0 | 0.90 |
| FCF Margin | 12.0%+7.7pp | 4.3%+6.1pp | -1.8%-0.1pp | -1.7%-4.6pp | 2.9%-5.3pp | 8.3%+28.2pp | -19.9%-10941.6pp | 10921.8% |
Similar Companies
Frequently Asked Questions
What is Fresenius Med Cr's annual revenue?
Fresenius Med Cr (FMS) reported $17.9B in total revenue for fiscal year 2016. This represents a 7.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Fresenius Med Cr's revenue growing?
Fresenius Med Cr (FMS) revenue grew by 7% year-over-year, from $16.7B to $17.9B in fiscal year 2016.
Is Fresenius Med Cr profitable?
Yes, Fresenius Med Cr (FMS) reported a net income of $1.2B in fiscal year 2016, with a net profit margin of 6.9%.
What is Fresenius Med Cr's earnings per share (EPS)?
Fresenius Med Cr (FMS) reported diluted earnings per share of $4.06 for fiscal year 2016. This represents a 20.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Fresenius Med Cr's EBITDA?
Fresenius Med Cr (FMS) had EBITDA of $3.4B in fiscal year 2016, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Fresenius Med Cr have?
As of fiscal year 2016, Fresenius Med Cr (FMS) had $747.2M in cash and equivalents against $7.2B in long-term debt.
What is Fresenius Med Cr's gross margin?
Fresenius Med Cr (FMS) had a gross margin of 32.3% in fiscal year 2016, indicating the percentage of revenue retained after direct costs of goods sold.
What is Fresenius Med Cr's operating margin?
Fresenius Med Cr (FMS) had an operating margin of 14.7% in fiscal year 2016, reflecting the profitability of core business operations before interest and taxes.
What is Fresenius Med Cr's net profit margin?
Fresenius Med Cr (FMS) had a net profit margin of 6.9% in fiscal year 2016, representing the share of revenue converted into profit after all expenses.
Does Fresenius Med Cr pay dividends?
Yes, Fresenius Med Cr (FMS) paid $0.80 per share in dividends during fiscal year 2016.
What is Fresenius Med Cr's return on equity (ROE)?
Fresenius Med Cr (FMS) has a return on equity of 11.5% for fiscal year 2016, measuring how efficiently the company generates profit from shareholder equity.
What is Fresenius Med Cr's free cash flow?
Fresenius Med Cr (FMS) generated $1.1B in free cash flow during fiscal year 2016. This represents a 10.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Fresenius Med Cr's operating cash flow?
Fresenius Med Cr (FMS) generated $2.1B in operating cash flow during fiscal year 2016, representing cash generated from core business activities.
What are Fresenius Med Cr's total assets?
Fresenius Med Cr (FMS) had $26.9B in total assets as of fiscal year 2016, including both current and long-term assets.
What are Fresenius Med Cr's capital expenditures?
Fresenius Med Cr (FMS) invested $1.0B in capital expenditures during fiscal year 2016, funding long-term assets and infrastructure.
How much does Fresenius Med Cr spend on research and development?
Fresenius Med Cr (FMS) invested $162.4M in research and development during fiscal year 2016.
How many shares does Fresenius Med Cr have outstanding?
Fresenius Med Cr (FMS) had 306M shares outstanding as of fiscal year 2016.
What is Fresenius Med Cr's current ratio?
Fresenius Med Cr (FMS) had a current ratio of 1.45 as of fiscal year 2016, which is considered adequate.
What is Fresenius Med Cr's debt-to-equity ratio?
Fresenius Med Cr (FMS) had a debt-to-equity ratio of 0.67 as of fiscal year 2016, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Fresenius Med Cr's return on assets (ROA)?
Fresenius Med Cr (FMS) had a return on assets of 4.6% for fiscal year 2016, measuring how efficiently the company uses its assets to generate profit.
What is Fresenius Med Cr's Altman Z-Score?
Fresenius Med Cr (FMS) has an Altman Z-Score of 2.15, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Fresenius Med Cr's Piotroski F-Score?
Fresenius Med Cr (FMS) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Fresenius Med Cr's earnings high quality?
Fresenius Med Cr (FMS) has an earnings quality ratio of 1.72x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Fresenius Med Cr cover its interest payments?
Fresenius Med Cr (FMS) has an interest coverage ratio of 5.8x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Fresenius Med Cr?
Fresenius Med Cr (FMS) scores 54 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.